对患有凝血因子缺陷的患者使用的血栓生成平台的比较分析:全面评估
Bauke Haisma1, Saskia E M Schols1, René G M van Oerle2
1Department of Hematology, Radboud university medical center, Geert Grooteplein Zuid 10, 5425 GA Nijmegen, the Netherlands; Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Geert Grooteplein Zuid 10, 5425 GA Nijmegen, the Netherlands.
血栓生成试验有效地检测四个平台的凝血因子缺陷. 具有较低组织因子和脂度的试剂最好用于识别患者的出血倾向.
科学领域:
- 血液学 血液学 血液学
- 血液静止 血液静止 血液静止
- 诊断检测试验 诊断检测试验
背景情况:
- 血生成试验 (TGA) 评估血液静止系统的功能.
- 现有四个半自动化平台:CAT,Nijmegen,ST Genesia和Ceveron s100. 这四个半自动化平台分别为:CAT,Nijmegen,ST Genesia和Ceveron s100. 这四个半自动化平台分别为:
- 先天性单一凝血因子缺陷会影响血液静止.
研究的目的:
- 将四个TGA平台的性能进行比较.
- 评估TGA检测先天性单个凝血因子缺陷的能力.
- 确定用于缺陷检测的最佳试剂.
主要方法:
- 在四个TGA平台上测试了组合的患者和对照样本.
- 使用的试剂具有不同的组织因子和脂度.
- 分析了峰值高度和血栓潜力,将结果正常化为健康对照.
主要成果:
- 所有平台和试剂都显示出较低的血栓潜力和缺陷样本中的峰值高度.
- 治疗出血倾向的试剂产生了最低的值.
- 更严重的缺陷与较低的峰值高度和血凝潜力相关.
结论:
- TGAs有效地将缺因子样本与健康对照区分开来.
- 发现了平台对平台的适度差异.
- 具有较低组织因子/脂度的试剂最适合用于检测因子缺乏.
更多相关视频
13:08Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
